We developed a polymerase chain reaction-based assay for FranciseUa tularensis which we evaluated by using spiked blood samples and experimentally infected mice. The assay detected both type A and type B F. tularensis at levels equivalent to one CFU/pl of spiked blood. Results from polymerase chain reaction-based assay of limiting dilutions of blood from mice infected with the live vaccine strain agreed closely with results from blood culture.
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Tularemia is a clinical syndrome caused by the facultative intracellular bacterium Francisella tularensis. There are two recognized biovars of the bacterium distributed over most of the temperate regions of the Northern Hemisphere. F. tularensis bv. tularensis (Jellison type A) is found in North America, primarily in the south central United States, and is the more pathogenic of the two biovars. F. tularensis type A causes several different disease syndromes depending on the method of exposure. Ulceroglandular infections are the most common type (ca. 80%) and are characterized by fever, swollen lymph nodes, and ulceration at the site of skin penetration, usually through the bite of an infected tick, mosquito, or deer fly; ingestion of F. tularensis-contaminated food or water produces oropharyngeal and/or gastrointestinal tularemia; and inhalation of aerosolized bacteria results in the pleuropulmonary form. Regardless of the route of inoculation, bacteria usually invade the regional lymph nodes and are disseminated via the systemic circulation to other organs.
F. tularensis bv. palaearctica (Jellison type B) is more widely distributed in nature and is found in Europe, Asia, and North America. It is considered to be less pathogenic than F. tularensis bv. tularensis, although studies have identified this biovar as a cause of disease in Finland (14) , Japan (7) , and the United States (6).
Although F. tularensis can be isolated from blood (8, 13) , diagnosis by this method is notoriously unreliable. In a recent study in the southwest central United States, bacteria were isolated from only 13.2% of laboratory-confirmed cases (13) . Laboratory confirmation is typically made by serodiagnosis (enzyme-linked immunosorbent assay or agglutination) (9, 11 PCR of purified DNA resulted in a product whose apparent molecular weight on agarose gel electrophoresis was consistent with the 250-bp predicted size (Fig. 1) 100 ,ug of proteinase K per ml). Total nucleic acid was extracted with phenol-chloroform-isoamyl alcohol and precipitated with ethanol. DNA was dissolved to its original volume in distilled water. PCR of a 5-pl1 aliquot of total nucleic acid extracted from these spiked blood samples (equivalent to DNA from 5 pl1 of blood) was tested in PCR, and the product was analyzed by dot blot. PCR product could be detected in tubes containing 1 CFU/pl of the LVS (5 CFU per reaction mix) (Fig. 2) and from blood samples equivalent to 1 CFU/,ul of blood (5 CFU per reaction mix).
The LVS, F. tularensis bv. palaearctica, while relatively avirulent in humans, produces disease in mice similar to that produced by type A in humans (4) . Intravenous inoculation of mice with 103 LVS bacteria produces a lethal infection terminating at approximately 72 h. We examined whole blood and plasma for the presence of bacteria. Blood was centrifuged at 1,500 x g for 5 min, and the number of bacteria in plasma was estimated by PCR and by culture. No organisms were detected in 10 ,ll of plasma by PCR, and inoculation of 1 ml of plasma onto supplemented MuellerHinton plates showed 20 CFU/ml of plasma. The negative PCR in this case is probably due to the small volume of plasma tested. The number of bacteria detected by culture is equivalent to 1 CFU/50 pll of plasma. Extraction and concentration of DNA from larger volumes of plasma would increase the chances of detection by PCR.
An estimate of the numbers of organisms per unit volume of whole blood was made by PCR with limiting dilution and compared to culture results. Blood samples were serially diluted 10-fold, and DNA was extracted from a 500-,ul aliquot at each dilution. A 1-ml aliquot of blood at each dilution was also plated, and CFU were counted 4 days later. The PCR assay for F. tularensis is a sensitive method for the detection of this pathogen in blood. Tularemia is problematic to diagnose in the acute phase of the disease, since the organism is difficult and very slow to culture. Under ideal laboratory conditions in which special culture media were available and in which a rough concentration of F. tularensis was known, we were able to demonstrate, by culture, significant numbers of bacteria in whole blood and few pathogens in plasma. In clinical situations, however, the conditions for isolation of F. tularensis are far from ideal. Culture of this organism from blood samples of known cases of tularemia is less than 20%. The semiquantitative results we obtained by using limiting dilutions of blood show that DNA amplification is comparable to blood culture in its ability to detect the organism. Dilution from a whole-blood extract gave a higher estimated count of bacteria and appears to be more sensitive. The assay was able to detect a single bacterium in a 5-,u aliquot of spiked human blood (Fig. 2) . Thus PCR was equally as sensitive as culture in detecting F. tularensis under ideal conditions. PCR can be expected to be considerably more reliable and specific in clinical situations. 
